17α-Estradiol: A less-feminizing estrogen

Drug Development Research

Volumn 69, Issue 4, 2008, Pages 177-184

  Moos, Walter H ^a,b,c   Dykens, James A ^a,d   Howell, Neil ^a  

^a MIGENIX Corporation   (United States)

^b SRI INTERNATIONAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

17 estradiol; 17 estradiol; Alzheimer's disease; Estradiol; Estrogenicity; Estrogens; Estrone; Hormonal; Less feminizing; Neurodegeneration; Neuroprotection; Non feminizing; Premarin; Uterotrophic; Women's health initiative (VVHI)

Indexed keywords

17ALPHA ESTRADIOL; CONJUGATED ESTROGEN; DONEPEZIL; ESTRADIOL; ESTREN; ESTRIOL; ESTROGEN; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; J 861; MEMANTINE; MITO 4565; MX 4565; UNCLASSIFIED DRUG; ZYC 5;

ALZHEIMER DISEASE; COGNITION; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN ACTIVITY; FEMINIZATION; HEALTH CARE COST; HUMAN; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; REVIEW;

EID: 50849128483     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20244     Document Type: Review

References (77)

1. Asthana S, Baker LD, Craft S, Stanczyk FZ, Veith RC, Raskind MA, Plymate SR. 2001. High-dose estradiol improves cognition for women with AD. Neurology 57:605-612.
2. Barker KL, Anderson JM. 1968. Displacement of estradiol-17-beta from the uterus by estradiol-17-alpha: effect on template capacity of uterine chromatin. Endocrinology 83:585-591.
3. Baumgartner AR. 1999. Probing Premarin. Can Med Assoc J 161:1390.
4. Bluming AZ. 2004. Hormone replacement therapy: the debate should continue. Geriatrics 59:30-37.
5. Brinton RD. 2004. Requirements of a brain selective estrogen: advances and remaining challenges for developing a Neuro-SERM. J Alzheimer Dis 6(Suppl):S27-S35.
6. Chakrabarti E, Wang J, Claire-Olsen J, Smith JD. 200.5. Lack of protective effect of estrogens on cerebral Aβ levels in intact female and male APP transgenic mice. Drug Dev Res 66:136-141.
7. Clark JH, Williams M, Upchurch S, Eriksson H, Helton E, Markaverich BM. 1982. Effects of estradiol-17 alpha on nuclear occupancy of the estrogen receptor, stimulation of nuclear type II sites and uterine growth. J Steroid Biochem 16:323-328.
8. Cordey M, Gundimeda U, Gopalakrishna R, Pike CJ. 2005. The synthetic estrogen 4-estren-3 alpha, 17 beta-diol (estren) induces estrogen-like neuroprotection. Neurobiol Dis 19:331-339.
9. Cummings JL. 2004. Alzheimer's disease. N Engl J Med 351:56-67.
10. Dey M, Lyttle GR, Picar JH. 2000. Recent insights into the varying activity of estrogens. Maturitas 34:S25-S33.
11. Dorfman RI, Kinel FA. 1966. Uterotrophic activity of various phenolic steroids. Acta Endocrinol (Copenh) 52:619-626.
12. Dykens JA, Simpkins JW, Wang J, Gordon K. 2003. Polycyclic phenols, estrogens and neuroprotection: a proposed mitochondrial mechanism. Exp Gerontol 38:101-107.
13. Dykens JA, Moos WH, Howell N. 2005. Development of 17α-estradiol as a neuroprotective therapeutic: rationale and results from a Phase I clinical study. Ann NY Acad Sci 1052:116-135.
14. Edwards DP, McGuire WL. 1980. 17 alpha-Estradiol is a biologically active estrogen in human breast cancer cells in tissue culture. Endocrinology 107:884-891.
15. Eldridge JC, Cidlowski JA, Muldoon TG. 1986. Correlation between LH and estrogen receptor turnover in pituitary and hypothalamus of castrate rats following estrogen agonists and antagonists. J Steroid Biochem 24:623-628.
16. Grady D. 2003. Postmenopausal hormones - therapy for symptoms only. N Engl J Med 348:1835-1837.
17. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. 2002. Production and actions of estrogens. JAMA 346:340-352.
18. Harman SM, Naftolin F, Brinton EA, Judelson DR. 2005. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann NY Acad Sci 1052:43-56.
19. Hart JE. 1990. Endocrine pathology of estrogens. Species differences. Pharmacol Ther 47:203-218.
20. Heywood R, Wadsworth PF 1980. The experimental toxicology of estrogens. Pharmacol Ther 8:125-142.
21. Hilgar, AG, Palmore Jr J. 1968. The uterotropic evaluation of steroids and other compounds - assay 2. In: Hilgar AG, Trench LC, editors. Endocrine bioassay data. Part VI. Bethesda, MD: National Cancer Institute. 181p.
22. Hobe G, Schon R, Goncharov N, Katsiya G, Koryakin M, Gesson-Cholat I, Oettel M, Zimmermann H. 2002. Some new aspects of 17alpha-estradiol metabolism in man. Steroids 67:883-893.
23. Honjo H, Iwasa K, Kawata M, Fushiki S, Hosoda T, Tatsumi H, Oida N, Mihara M, Hirasuoi Y, Yamamoto H, Kikuchi N, Kitawaki J. 2005. Progestins and estrogens and Alzheimer's disease. J Steroid Biochem Mol Biol 93:305-308.
24. Holinka CF, Hata H, Kuramoto H, Gurpide E. 1986. Effects of steroid hormone and antisteroids on alkaline phosphatase activity in human endometrial cancer cells (Ishikawa line). Cancer Res 46:2771-2774.
25. Howard RP, Keaty EC. 1971. Evaluation of equilin 3-monosnlfate and other estrogens. Comparisons by study of urinary gonadotropins in women. Arch Intern Med 128:229-234.
26. Howell N, Dykens J, Moos WH. 2005a. Alzheimer's disease, estrogens, and clinical trials: a case study in drug development for complex disorders. Drug Dev Res 66:53-77.
27. Howell N, Dykens J, Moos WH. 2005b. Estrogens and neuroprotection: desperate housewives, lost, and survivor. Drug Dev Res 66:51-52.
28. Huggins C, Jensen EV, Cleveland AS. 1954. Chemical structure of steroids in relation to promotion of growth of the vagina and uterus of the hypophysectomized rat. J Exp Med 100:225-243.
29. Huggins C, Jensen EV. 1955. The depression of estrone-induced uterine growth by phenolic estrogens with oxygenated functions at positions 6 or 16: the impeded estrogens. J Exp Med 102:335-346.
30. Iglesias R, Mardones E, Lipschutz A. 1951. Comparative experiments with the prolonged administration of α and β oestradiol. Acta Physiol Lat Am 1:67-73.
31. Karg H, Vogt K. 1978. Control of hormone treatment in animals and residues in meat - regulatory aspects and approaches in methodology. J Assoc Off Anal Chem 61:1201-1208.
32. Kneifel MA, Leyrus SP, Fletcher E, Weber T, Mangel WF, Katzenellenbogen BS. 1982. Uterine plasminogen activator activity: modulation by steroid hormones. Endocrinology 111:493-499.
33. Korenman SG. 1969. Comparative binding affinity of estrogens and its relation to estrogenic potency. Steroids 13:163-177.
34. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson J-A. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138:863-870.
35. Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson J-A. 1998. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263.
36. Lauritzen C. 1969. Oestrogenaktivität von 17α-oestradiol, equilin, equilenin und ihren sulfokonjugaten im tierversuch und beim menschen. Symp Deutsch Gesell Endokrinol 15:42-144.
37. Levin-Allerhand JA, Lominska CE, Wang J, Smith JD. 2002. 17α-estradiol and 17β-estradiol treatments are effective in lowering cerebral amyloid-β levels in AβPPSWE transgenic mice. J Alzheimer Dis 4:449-457.
38. 5 adrenal steroids. Endocrinology 127:2757-2762.
39. Lotz W. 1978. Biological activities and receptor affinities of some natural and synthetic oestrogens and their D-homo analogues. Experientia 34:1373-1374.
40. MacLusky NJ, Krey LC, Parsons B, Merriam GR, Lorianx DL, Pfeiffer DG, Naftolin F. 1986. Are catechol oestrogens obligatory mediators of oestrogen action in the central nervous system? II. Potencies of natural and synthetic oestrogens for induction of gonadotropin release and female sexual behaviour in the rat. J Endocrinol 110:499-505.
41. Maki PM. 2004. Hormone therapy and risk for dementia: where do we go from here? Gynecol Endocrinol 19:354-359.
42. Merchenthaler I, Funkhouser JM, Carver JM, Lundeen SG, Ghosh K, Winneker RC. 1998. The effect of estrogen sand antiestrogens in a rat model for hot flush. Maturitas 30:307-316.
43. Meyer III WJ, Henneman DH, Keiser HR, Bartter FC. 1976. 17α Estradiol: separation of estrogen effect on collagen from other clinical and biochemical effects in man. Res Commun Chem Pathol Pharmacol 13:685-695.
44. Moll GW, Rosenfeld RL. 1984. Direct inhibitory effect of estradiol on pituitary luteinizing hormone responsiveness to luteinizing hormone releasing hormone is specific and of rapid onset. Biol Reprod 30:59-66.
45. Morales LBJ, Loo KK, Liu H-B, Peterson C, Tiwari-Woodruff S, Voskuhl RR. 2006. Treatment with an estrogen receptor α ligand is neuroprotective in experimental autoimmune encephalomyelitis. J Neurosci 26:6823-6833.
46. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R, Thal LJ. 2000. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283:1007-1015.
47. Norman AW, Mizwicki MT, Norman DPG. 2004. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Disc 3:27-41.
48. Oettel M. 1999. Estrogens and antiestrogens in the male. In: Oettel M, Schillinger E, editors. Estrogens and antiestrogens. II. Pharmacology and clinical application of estrogens and antiestrogens. Berlin: Springer. p 505-571.
49. O'Neill K, Chen S, Brinton RD. 2004. Impact of the selective estrogen receptor modulator, tamoxifen, on neuronal outgrowth and survival following toxic insults associated with aging and Alzheimer's disease. Exp Neurol 188:268-278.
50. Orfanos CE, Vogels L. 1980. Local therapy of androgenetic alopecia with 17α-estradiol. A controlled, randomized double-blind study. Dermatologica 161:124-132.
51. Papendorp JT, Schatz RW, Soto AM, Sonnenschein C. 1985. On the role of 17 alpha-estradiol and 17 beta-estradiol in the proliferation of MCF7 and T47D-A11 human breast tumor cells. J Cell Physiol 125:591-595.
52. Perez E, Liu R, Yang SH, Cai ZY, Covey DF, Simpkins JW. 2005. Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res 1038:216-222.
53. Perez E, Cai ZY, Covey DF, Simpkins JW. 2006. Neuroprotective effects of estratriene analogs: structure-activity relationships and molecular optimization. Drug Dev Res 66:78-92.
54. Rambo CO, Szego CM. 1983. Estrogen action at endometrial membranes: alterations in luminal surface detectable within seconds. J Cell Biol 97:679-685.
55. Rapp SR, Espeland MA, Shumaker SA, Henderson VW, Brunner RL, Manson JE, Gass MLS, Stefanick ML, Lane DS, Hays J, Johnson KC, Coker LH, Dailey M, Bowen D. 2003. Effect of estrogen plus progestin on global cognitive function in post-menopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2663-2672.
56. Saldarini RJ, Hilliard J, Abraham GE, Sawyer CH. 1970. Relative potencies of 17α- and 17β-estradiol in the rabbit. Biol Reprod 3:105-109.
57. Schriefers H, Wright MC, Rozman T, Hevert F. 1991. Inhibition of testosterone metabolism by 17-alpha-estradiol in rat liver slices. Arzneim Forsch 41:1186-1189.
58. Schröder J, Kaufmann G, Oettel M, Römer W, Sobek L. 1997. Estradiol-17α - a reasonable hormone replacement for the aging male? Maturitas 27(Suppl):216.
59. Shumaker SA, Legault C, Rapp SR, Thai L, Wallace RB, Ockene JK, Hendrix SL, Jones III BN, Assaf AR, Jackson RD, Kotchen JM, Wassertheil-Smoller S, Wactawski-Wende J. 2003. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289:2651-2662.
60. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, Fillit H, Stefanick ML, Hendrix SL, Lewis CE, Masaki K, Coker LH. 2004. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. Women's Health Initiative Memory Study. JAMA 291:2947-2958.
61. Sicotte NL, Liva SM, Klutch R, Pfieffer P, Bouvier S, Odesa S, Wu TCJ, Voskuhl RR. 2002. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 52:421-428.
62. Simpkins JW, Yang SH, Wen Y, Singh M. 2005. Estrogens, progestins, menopause and neurodegeneration: basic and clinical studies. Cell Mol Life Sci 62:271-280.
63. Singh M, Dykens JA, Simpkins JW. 2006. Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med 231:514-521.
64. Stack G, Korach K, Gorski J. 1989. Relative mitogenic activities of various estrogens and antiestrogens. Steroids 54:227-243.
65. Stern MD. 1982. Pharmacology of conjugated oestrogens. Maturitas 4:333-339.
66. Toran-Allerand CD, Guan X, MacLusky NJ, Horvath TL, Diano S, Singh M, Connolly Jr ES, Nethrapalli IS, Tinnikov AA. 2002. ER-X: a novel, plasma membrane-associated, putative estrogen receptor that is regulated during development and after ischemic brain injury. J Neurosci 22:8391-8401.
67. Toran-Allerand CD, Tinnikov AA, Singh RJ, Nethrapalli IS. 2005. 17α-estradiol: a brain-active estrogen? Endocrinology 146: 3843-3850.
68. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. 2003. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 289:2673-2684.
69. Westerholm B. 1980. Clinical toxicology of estrogens. Pharmacol Ther 10:337-349.
70. Wickelgren I. 2003. Estrogen research: brain researchers try to salvage estrogen treatments. Science 302:1138-1139.
71. Woolley CS. 2007. Acute effects of estrogen on neuronal physiology. Annu Rev Pharmacol Toxicol 47:657-680.
72. Xia S, Cai ZY, Thio LL, Kim-Han JS, Dugan LL, Covey DF, Rothman SM. 2002. The estrogen receptor is not essential for all estrogen neuroprotection: new evidence from a new analog. Neurobiol Dis 9:282-293.
73. Yang S-H, Shi J, Day AL, Simpkins JW. 2000. Estradiol exerts neuroprotective effects when administered after ischemic insult. Stroke 31:745-750.
74. Yang S-H, Liu R, Perez EJ, Wen Y, Stevens Jr SM, Valencia T, BrunZinkernagel A-M, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW 2004. Mitochondrial localization of estrogen receptor β. Proc Natl Acad Sci USA 101:4130-4135.
75. Zandi PP, Carlson MC, Plassinan BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JCS. 2002. Hormone replacement therapy and incidence of Alzheimer disease in older women. The Cache County study. JAMA 288:2123-2129.
76. Zhao L, Brinton RD. 2005. Estrogen receptor β as a therapeutic target for promoting neurogenesis and preventing neurodegeneration. Drug Dev Res 66:103-117.
77. Zhao L, Brinton RD. 2006. Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease. BMC Neurosci 7:24.